Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
29.83
+0.57 (+1.95%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
Next >
FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma
January 06, 2023
From
Genentech
Via
Business Wire
Big Health Care Stocks to Watch in the New Year
December 29, 2022
Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.
Via
MarketBeat
FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma
December 22, 2022
From
Genentech
Via
Business Wire
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
December 21, 2022
From
Genentech
Via
Business Wire
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
December 19, 2022
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum
Via
MarketBeat
OTC Market Group’s Most Active List In November: A Dive Into The Names Experiencing Volume Changes
December 14, 2022
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ)...
Via
TheNewswire.com
Topics
ETFs
Economy
Stocks
Exposures
Interest Rates
US Equities
Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
December 12, 2022
From
Spark Therapeutics, Inc.
Via
GlobeNewswire
Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
December 12, 2022
From
Genentech
Via
Business Wire
Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022
December 11, 2022
From
Genentech
Via
Business Wire
Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth
December 11, 2022
From
Genentech
Via
Business Wire
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up
December 01, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug...
Via
FinancialNewsMedia
Exposures
Product Safety
The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group’s Most-Active List In October
November 15, 2022
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 8.13% in October — its second-largest monthly increase in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ) and the SPDR Dow Jones...
Via
TheNewswire.com
Topics
ETFs
Stocks
Exposures
US Equities
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies
November 14, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 14, 2022 – USA News Group – English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his...
Via
FinancialNewsMedia
Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer’s Disease
November 14, 2022
From
Genentech
Via
Business Wire
Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs
November 03, 2022
From
Genentech
Via
Business Wire
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
October 28, 2022
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ) and the SPDR Dow Jones Industrial Average...
Via
TheNewswire.com
Topics
ETFs
Stocks
Exposures
US Equities
Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)
October 27, 2022
From
Genentech
Via
Business Wire
Early Treatment With Genentech’s Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile
October 26, 2022
From
Genentech
Via
Business Wire
Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022
October 19, 2022
From
Genentech
Via
Business Wire
Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)
October 12, 2022
From
Genentech
Via
Business Wire
Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche
September 07, 2022
From
Good Therapeutics
Via
Business Wire
FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
August 16, 2022
From
Genentech
Via
Business Wire
Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older
August 11, 2022
From
Genentech
Via
Business Wire
Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results
August 02, 2022
From
Genentech
Via
Business Wire
Genentech to Present Scientific Progress Across Alzheimer’s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting
July 28, 2022
From
Genentech
Via
Business Wire
New Two-Year Data Confirm Genentech’s Vabysmo Improves Vision With Fewer Treatments for People With Wet Age-Related Macular Degeneration
July 14, 2022
From
Genentech
Via
Business Wire
New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
July 11, 2022
From
Genentech
Via
Business Wire
FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma
July 06, 2022
From
Genentech
Via
Business Wire
Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
June 16, 2022
From
Genentech
Via
Business Wire
Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting
June 10, 2022
From
Genentech
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.